X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
X4 Pharmaceuticals (XFOR), a company focused on rare immune system diseases, has scheduled its fourth-quarter and full-year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.
Investors and interested parties can access the conference call by dialing 1-800-267-6316 (US) or 1-203-518-9783 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.
X4 Pharmaceuticals (XFOR), un'azienda focalizzata sulle malattie rare del sistema immunitario, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 25 marzo 2025. L'azienda ospiterà una conferenza telefonica e una webcast alle 8:30 a.m. ET dello stesso giorno.
Gli investitori e le parti interessate possono accedere alla conferenza telefonica componendo il numero 1-800-267-6316 (USA) o 1-203-518-9783 (Internazionale) utilizzando l'ID della conferenza: X4PHARMA. Una webcast in diretta sarà disponibile attraverso il sito web delle relazioni con gli investitori di X4, con una registrazione accessibile dopo la chiamata.
X4 Pharmaceuticals (XFOR), una empresa centrada en enfermedades raras del sistema inmunológico, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 25 de marzo de 2025. La empresa llevará a cabo una llamada de conferencia y una transmisión web a las 8:30 a.m. ET el mismo día.
Los inversores y partes interesadas pueden acceder a la llamada de conferencia marcando el 1-800-267-6316 (EE. UU.) o el 1-203-518-9783 (Internacional) utilizando el ID de conferencia: X4PHARMA. Una transmisión en vivo estará disponible a través del sitio web de relaciones con los inversores de X4, con una repetición accesible después de la llamada.
X4 Pharmaceuticals (XFOR), 희귀 면역 질환에 중점을 둔 회사가 2025년 3월 25일에 2024년 4분기 및 연간 재무 결과 발표를 예정했습니다. 회사는 같은 날 오전 8시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최할 것입니다.
투자자 및 관심 있는 당사자는 1-800-267-6316 (미국) 또는 1-203-518-9783 (국제)로 전화하여 회의 ID: X4PHARMA를 사용하여 컨퍼런스 콜에 접속할 수 있습니다. X4의 투자자 관계 웹사이트를 통해 생중계 웹캐스트가 제공되며, 통화 후 다시보기도 가능합니다.
X4 Pharmaceuticals (XFOR), une entreprise axée sur les maladies rares du système immunitaire, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 25 mars 2025. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 8h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en composant le 1-800-267-6316 (États-Unis) ou le 1-203-518-9783 (International) en utilisant l'ID de conférence : X4PHARMA. Un webinaire en direct sera disponible sur le site des relations investisseurs de X4, avec un replay accessible après l'appel.
X4 Pharmaceuticals (XFOR), ein Unternehmen, das sich auf seltene Erkrankungen des Immunsystems konzentriert, hat die Bekanntgabe seiner Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 für den 25. März 2025 angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten.
Investoren und interessierte Parteien können die Telefonkonferenz unter der Nummer 1-800-267-6316 (USA) oder 1-203-518-9783 (International) unter Verwendung der Konferenz-ID: X4PHARMA erreichen. Ein Live-Webcast wird über die Investor-Relations-Website von X4 verfügbar sein, mit einer Wiederholung, die nach dem Anruf zugänglich ist.
- None.
- None.
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.
The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
X4 Media Contact:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
FAQ
When will X4 Pharmaceuticals (XFOR) release its Q4 and full-year 2024 earnings?
What time is X4 Pharmaceuticals' (XFOR) Q4 2024 earnings call?
How can investors join X4 Pharmaceuticals' (XFOR) Q4 2024 earnings call?
Will there be a replay available for X4 Pharmaceuticals' (XFOR) Q4 2024 earnings call?
